Breaking News Instant updates and real-time market news.

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55

Fly Intel: After Hours Movers

DOWN AFTER EARNINGS: Beacon Roofing (BECN) down 8.3% after Q2 guidance... SAExploration Holdings (SAEX) down 4.2%. ALSO LOWER: iQUIYI (IQ) down 4.9% after offering of convertible notes... MyoKardia (MYOK) down 3.6% after equity offering... CytomX (CTMX) down 1.6% after resignation of CFO. Movers as of 18:45ET.

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

BECN Beacon Roofing
$34.14

0.81 (2.43%)

02/25/19
02/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Antares Pharma (ATRS) initiated with an Outperform at Cowen. 2. New Fortress Energy (NFE) initiated with a Buy at Citi and Stifel, an Overweight at Morgan Stanley, an Equal Weight at Barclays and an Oupterform at JMP Securities and Evercore ISI. 3. Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Flowr (FLWPF), Organigram (OGRMF) and The Green Organic Dutchman (TGODF) initiated with a Buy at Jefferies, Canopy Growth (CGC) and Emerald Health Therapeutics (EMHTF) initiated with a Hold, Cronos Group (CRON) and HEXO (HEXO) initiated with an Underperform. 4. Pulse Biosciences (PLSE) initiated with a Buy at H.C. Wainwright. 5. Beacon Roofing (BECN) initiated with a Neutral at Buckingham, while the firm initiated BMC Stock Holdings (BMCH) and TopBuild (BLD) with a Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/25/19
BUCK
02/25/19
INITIATION
BUCK
Neutral
Beacon Roofing initiated with a Neutral at Buckingham
Buckingham analyst Megan McGrath initiated Beacon Roofing with a Neutral and $38 price target citing uncertainties around the Allied integration and roofing demand. McGrath would like to see a positive turn in roofing or EBITDA margin improvement before turning more positive on shares.
02/08/19
RHCO
02/08/19
NO CHANGE
Target $44
RHCO
Buy
Beacon Roofing price target raised to $44 from $38 at SunTrust
SunTrust analyst Keith Hughes raised his price target on Beacon Roofing to $44 and kept his Buy rating after its Q1 earnings beat and maintained guidance for the first time in several quarters. The analyst cites the company's continued price / costs gains and also points to its "solid organic growth" in January even though it is typically a weak month on a seasonal basis. Hughes expects Beacon Roofing comps to improve from the unusually weak for storm activity 2018.
12/14/18
12/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Sell from Neutral at Goldman Sachs with analyst Robert Jones saying he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." 2. Cisco (CSCO) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying strengthening information technology spending, an innovation-led refresh cycle, and a rising software mix have lifted Cisco's multiple and its shares to post-recession highs. 3. Universal Health (UHS) downgraded to Sell from Neutral at Goldman Sachs with analyst Stephen Tanal saying a "healthy" macro environment helps acute hospitals' commercial mix, but behavioral health providers like Universal Health over-index to Medicaid and Medicare, "leaving them less exposed to the supportive backdrop." 4. Beacon Roofing (BECN) downgraded to Neutral from Outperform at Wedbush with analyst Jay McCanless saying that yesterday's investor day did not provide any new catalysts to raise EPS estimates or price target. 5. Kaman (KAMN) downgraded to Underweight from Neutral at JPMorgan with analyst Seth Seifman saying he values the stock at 14 times his 2020 earnings per share estimate of $4.05 while adding 15c for potentially accretive M&A, given the company's balance sheet capacity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SAEX SAExploration
$4.03

0.13 (3.33%)

IQ iQIYI
$24.01

-0.86 (-3.46%)

02/22/19
NWST
02/22/19
UPGRADE
NWST
Buy
iQIYI upgraded to Buy from Neutral at New Street
03/15/19
TIGR
03/15/19
INITIATION
TIGR
Buy
iQIYI initiated with a Buy at Tigress Financial
Tigress Financial analyst Aaron Ju initiated coverage earlier on iQIYI with a Buy rating, citing what he views as a leading position in the online streaming video sector and its ability to create high quality, original online content. Additionally, iQIYI's ongoing investment in technology should continue to drive its market share penetration, the analyst contends.
01/28/19
OPCO
01/28/19
NO CHANGE
Target $210
OPCO
Outperform
Baidu price target lowered to $210 from $230 at Oppenheimer
Oppenheimer analyst Jason Helfstein lowered his price target for Baidu (BIDU) to $210 from $230 on slower revenue, higher investments in 2019, his firm's recently lowered Ctrip (CTRP) price target and recent downward movement of iQIYI (IQ) shares. The analyst now expects Baidu to continue investing in key areas, such as content and sales and marketing in 2019, regardless of softer advertising industry trends. Additionally, he expects the recently announced CCTV CNY gala sponsorship to have a one-off negative impact on Q1 margins due to higher marketing dollars, but beneficial to user acquisition. Helfstein reiterates an Outperform rating on Baidu's shares.
01/14/19
OTRG
01/14/19
DOWNGRADE
OTRG
Mixed
iQIYI downgraded to Mixed from Positive at OTR Global
MYOK MyoKardia
$51.87

-2.44 (-4.49%)

02/21/19
BMOC
02/21/19
INITIATION
BMOC
Outperform
MyoKardia initiated with an Outperform at BMO Capital
BMO Capital analyst George Farmer initiated MyoKardia with an Outperform rating and $85 price target. The analyst said he would be a buyer on his view of the potential of lead drug, mavacamten, for treatment of hypertrophic cardiomyopathy. He added that the recent stock pullback caused by the loss of Sanofi (SNY) as an entrenched partner, which he believes mostly had to do with Sanofi pipeline re-prioritization, creates an attractive entry point for investment in MyoKardia.
01/03/19
MSCO
01/03/19
NO CHANGE
Target $70
MSCO
Overweight
MyoKardia shares oversold on Sanofi collaboration end, says Morgan Stanley
Morgan Stanley analyst Jeffrey Hung said MyoKardia (MYOK) management emphasized that Sanofi (SNY) wanted greater economics and maintained that efficacy and safety did not factor into Sanofi's decision to end their collaboration. His base case assumption is that MyoKardia will find another partner after more mature data are reported and he thinks the shares have been oversold following yesterday's announcement, Hung tells investors. He trimmed his price target on the stock to $70 from $72, but keeps an Overweight rating, stating that he believes the Phase 2 mavacamten data were promising and sees multiple catalysts over the next year.
03/05/19
BMOC
03/05/19
NO CHANGE
Target $90
BMOC
Outperform
MyoKardia price target raised to $90 from $85 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on MyoKardia to $90 and kept her Outperform rating, saying its latest PIONEER open-label extension results support the mavacamten efficacy and safety in oHCM patients while also posing a "positive read-through to the ongoing Phase 3 EXPLORER trial for oHCM". Bania notes that her new price target reflects a 10% increase in probability of success of mavacamten in oHCM and nHCM to 70% and 50% respectively.
01/16/19
CANT
01/16/19
NO CHANGE
Target $90
CANT
Overweight
Cantor reiterates Overweight rating on MyoKardia with $90 target
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on MyoKardia (MYOK) with a $90 price target. The analyst updated her model after MyoKardia partner Sanofi (SNY) decided not to continue the companies' collaboration. Young's model now assumes MyoKardia regaining full global commercial rights to both mavacamten and MYK-491 and also assuming sole responsibility for future development costs. However, her $90 target for MyoKardia shares remains unchanged.
CTMX CytomX Therapeutics
$10.76

0.33 (3.16%)

03/11/19
03/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TCR2 Therapeutics (TCRR) initiated with an Outperform at SVB Leerink, Wedbush, and BMO Capital, while being initiated with a Buy at Jefferies. 2. Barings BDC (BBDC) resumed with an Outperform at Wells Fargo. 3. Avedro (AVDR) initiated with an Overweight at JPMorgan while being initiated with an Outperform at SVB Leerink and Cowen. 4. Anchiano Therapeutics (ANCN) initiated with a Buy at Ladenburg and an Outperform at Oppenheimer. 5. CytomX Therapeutics (CTMX) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/11/19
LEHM
03/11/19
INITIATION
Target $16
LEHM
Overweight
CytomX Therapeutics initiated with an Overweight at Barclays
Barclays analyst Geoff Meacham started CytomX Therapeutics with an Overweight rating and $16 price target. The analyst believes the company's Probody technology could prove to be a successful approach in difficult-to-treat tumors, with "several opportunities for value-driving commercial assets over the mid /long-term." De-risking of CytomX's platform and lead programs will serve as a "major catalyst" for the stock in the intermediate-term, Meacham tells investors in a research note.
02/27/19
WEDB
02/27/19
NO CHANGE
Target $25
WEDB
Outperform
CytomX Therapeutics price target lowered to $25 from $35 at Wedbush
Wedbush analyst Robert Driscoll lowered his price target for CytomX Therapeutics to $25 from $35 after the company gave a detailed overview of its current pipeline and future opportunities, with updated data from studies of lead asset CX-072. In addition, CytomX Therapeutics presented an initial clinical dataset from the dose escalation portion of PROCLAIM-2009, which is evaluating the Probody Drug Conjugate CX-2009, he notes. The analyst sees share weakness following the update as a compelling buying opportunity, given CytomX Therapeutics' broad pipeline of differentiated Probody therapeutics. Driscoll reiterates an Outperform rating on the shares.
02/28/19
RHCO
02/28/19
NO CHANGE
Target $18
RHCO
Buy
CytomX Therapeutics price target lowered to $18 from $33 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on CytomX to $18 after its R&D day which provided an update on CX-072 and initial data from CX-2009. The analyst notes that the initial response in the study of the latter saw some potential concerns around its safety profile, but keeps his Buy rating on the stock longer term as he remains "encouraged by the biopharma validation of CytomX's platform through partnerships". Lawson adds that "CytomX's platform is potentially scalable not only many different antibodies but also expands the universe to potential targets".

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.